Clinical Trial: A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891560) titled 'A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma' on March 18.

Brief Summary: The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Adenoid Cystic Carcinoma

Intervention: DRUG: Enfortumab Vedotin

intravenously on Days 1, 8 and 15 of a 28-day cycle

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Memorial Sloan Kettering Cancer Center

Published by HT Digital Content Services with permission from Health Daily Digest....